Physician profile
Michael Mancuso
NPI 1962510800
$2,814.46
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $205 · 2021: $109 · 2022: $713 · 2023: $838 · 2024: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.79 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $723.15 | 2022-2024 | Vtama |
| Leo Pharma INC. | $620.01 | 2019-2024 | Adbry |
| Janssen Biotech, INC. | $594.13 | 2019-2023 | Tremfya |
| Prugen, INC. Pharmaceuticals | $219.33 | 2019 | |
| Genzyme Corporation | $166.37 | 2022-2024 | |
| Amgen INC. | $109.49 | 2020-2023 | Otezla |
| Abbvie INC. | $108.67 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2019 | |
| Ucb, INC. | $52.88 | 2024 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.51 | 2022 | |
| Lilly USA, LLC | $19.84 | 2021 | |
| Arcutis Biotherapeutics, INC. | $17.03 | 2023 | |
| Pfizer INC. | $16.65 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $15.63 | 2024 | Sotyktu |
| Aclaris Therapeutics, INC. | $14.63 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $13.13 | 2022 | |
| Sun Pharmaceutical Industries INC. | $11.51 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mancuso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.